Ispire Collaborates with Berify and Chemular on Blockchain Technology

Business by 2FIRSTS.ai

Feb.23.2024

Ispire Collaborates with Berify and Chemular on Blockchain Technology

Ispire collaborates with Touchpoint World Wide Inc. and Chemular International Inc. to accelerate e-cigarette technology innovation in a new venture.

According to a report by UPI on February 22nd, Ispire (ISPIRE) has announced a partnership with Touchpoint World Wide Inc. (Berify, a platform specializing in linking physical products to the digital world, digital engagement, and brand protection) and Chemular International Inc to establish a joint venture.

This joint venture will focus on accelerating innovation in the e-cigarette technology sector, including the development of safe, user-friendly age verification and age restriction vaporized nicotine device solutions.

Inspire Technology Company's Co-CEO Michael Wang stated, "By combining our collective expertise in hardware, blockchain, and regulatory consulting, our goal is to set new standards for age verification, safety, and overall quality in the e-cigarette industry. We hope this joint venture will bring significant advancements in device control, safety, anti-counterfeiting, and enhanced user experience, ultimately improving overall market and consumer satisfaction."

References:

[1] Ispire, Berify and Chemular to Propel Innovation in Vape Hardware Manufacturing Industry

Also Read:

[1] ISPIRE Reports Strong Growth in Q2 FY2024: Operating Expenses Surge to $10.3 Million, Net Loss at $4 Million

[2] Joint Venture Between Ispire and Berify for PMTA and Software Development

#North America #United States #Open system e-cigarettes #Technology.

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

Copyright

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months

The U.S. Food and Drug Administration (FDA) has added Cytisinicline, a plant-based therapy developed by Achieve Life Sciences for nicotine vaping addiction, to its new National Priority Voucher (CNPV) program. The initiative shortens drug review timelines from 10–12 months to just 1–2 months, expediting approval for treatments that address major public health needs.

Oct.20 by 2FIRSTS.ai

COP11 Update: Deep Divide Over Regulation of E-cigarettes and Nicotine Pouches as EU Pushes Back Against "Total Ban" Draft

At the ongoing COP11 in Geneva,a bloc led by Brazil and the Maldives has submitted a draft proposing "prohibition" as the primary policy path. In response, the European Union has submitted amendments requesting that the wording be adjusted to optional regulation, preserving the right of member states to decide on sales bans based on their own national laws.

Nov.21 by 2FIRSTS.ai

BAT Japan opens Glo flagship store in Tokyo's Ginza district, offering glo devices and tobacco sticks,

BAT Japan's flagship store in Tokyo's Ginza district opens, offering glo products, personalization services, and a VIP lounge.

Oct.20 by 2FIRSTS.ai

Imperial Brands launches ZONE nicotine pouches in the UK, covering the core 9–12 mg strength segment

Imperial Brands has launched its ZONE nicotine pouches in the UK, targeting the mainstream 9–12 mg nicotine strength segment. The brand debuts with five flavours at a recommended retail price of £6.50 per can. Mint variants currently account for around 70% of UK nicotine pouch sales, while fruit flavours are growing rapidly. ZONE will be distributed primarily through independent retail channels.